| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
BETHESDA, Md., November 10, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule thera... |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Employment Agreement (“Agreement”) is effective as of October 28, 2026 (“Effective Date”), by and between Gain Therapeutics, Inc. (“Company”) and Jeanette Weidner (“Executive”). |
| 01 Oct 2026 |
8-K: Other Events
On October 1, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of a poster at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seou... |
| 28 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of Gain Therapeutics, Inc. (the “Company”), notified the Company of his intention to resign from hi... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
BETHESDA, Md., August 11, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi... |
| 16 Jul 2026 |
8-K: Other Events
On July 16, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release and shareholder letter in which it announced, among other things, that its current cash and cash equivalents are anticipated to fund the Company’s operation... |
| 29 Jun 2026 |
8-K: Other Events
On June 29, 2026, Gain Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has authorized the Company’s Investigational New Drug application for GT-02287. FDA’s decision will allow initiation o... |
| 25 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 24, 2026, Gain Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”), at which a quorum was present. The matters voted on at the Annual Meeting were: (1) the election of seven directors... |
| 26 May 2026 |
8-K: Other Events
On May 26, 2026, Gain Therapeutics, Inc. (the “Company”) disclosed interim clinical and biomarker data from Part 2 (the nine-month extension) of its Phase 1b open-label clinical study of GT-02287 in patients with Parkinson’s disease with... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
BETHESDA, MD, May 11, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, ... |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
BETHESDA, MD, March 26, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies... |
| 18 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 |
| 03 Feb 2026 |
8-K: Regulation FD Disclosure
Corporate Presentation September 2024 GAIN THERAPEUTICS Corporate Deck February 2026 NASDAQ: GANX |
| 18 Dec 2025 |
8-K: Other Events
On December 18, 2025, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing results in exploratory endpoint from its Phase 1b clinical study of GT-02287 in people with Parkinson’s Disease (“PD”). All individuals with ... |
| 28 Nov 2025 |
8-K: Other Events
Re: Sale of Common Stock registered pursuant to Shelf Registration Statement on Form S-3 |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action |
| 14 Oct 2025 |
8-K: Regulation FD Disclosure
Corporate Presentation September 2024 GAIN THERAPEUTICS Parkinson’s Disease KOL Event Biomarkers, Clinical Endpoints, and the Path to Disease Modification Contextualizing the emerging data from GT - 02287 October 14, 2025 NASDAQ: GANX |
| 09 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 6, 2025, Eric Richman notified Gain Therapeutics, Inc. (the “Company”) that he was resigning from the Company’s Board of Directors (the “Board”), effective immediately. Mr. Richman’s resignation was not as a result of any disa... |
| 06 Oct 2025 |
8-K: Other Events
On October 6, 2025, Gain Therapeutics, Inc. (the “Company”) presented preliminary data from the Company’s ongoing Phase 1b clinical study of GT-02287 in people with Parkinson’s disease (“PD”) with or without a GBA1 mutation at the Intern... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated |
Loading...